Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jun;93(1):e77.
doi: 10.1002/cpcy.77.

Practical Guidelines for Collection, Manipulation and Inactivation of SARS-CoV-2 and COVID-19 Clinical Specimens

William Bain  1 , Janet S Lee  1 , Alan M Watson  2 , Molly S Stitt-Fischer  3
Affiliations

Practical Guidelines for Collection, Manipulation and Inactivation of SARS-CoV-2 and COVID-19 Clinical Specimens

William Bain et al. Curr Protoc Cytom. 2020 Jun.

Abstract

SARS-CoV-2 is a novel coronavirus that causes the acute respiratory disease-Coronavirus disease 2019 (COVID-19)-which has led to a global health crisis. Currently, no prophylactics or therapies exist to control virus spread or mitigate the disease. Thus, the risk of infection for physicians and scientists is high, requiring work to be conducted in Biosafety Level-3 (BSL-3) facilities if virus will be isolated or propagated. However, inactivation of the virus can enable safe handling at a reduced biosafety level, making samples accessible to a diverse array of institutions and investigators. Institutions of all types have an immediate need for guidelines that outline safe collection, handling, and inactivation of samples suspected to contain active virus. Here we provide a practical guide for physicians and researchers wishing to work with materials from patients who are COVID-19 positive or suspected positive. © 2020 Wiley Periodicals LLC. Basic Protocol 1: Practical guidelines for the safe collection and handling of specimens collected from COVID-19 and suspected COVID-19 patients Basic Protocol 2: Inactivating SARS-CoV-2.

Keywords: COVID-19; SARS-CoV-2; plaque assay; safety.

PubMed Disclaimer

References

Literature Cited

    1. Almazán, F. , DeDiego, M. L. , Galán, C. , Escors, D. , Álvarez, E. , Ortego, J. , … Enjanes, L. (2006). Construction of a severe acute respiratory syndrome coronavirus infectious cDNA clone and replicon to study coronavirus RNA synthesis. Journal of Virology, 80, 10900–10906. - PMC - PubMed
    1. Bisht, P. , Mohapatra, J. K. , Subramaniam, S. , Das, B. , Pande, V. , Biswal, J. K. , … Pattnaik, B. (2014). Efficient rescue of foot‐and‐mouth disease virus in cultured cells transfected with RNA extracted from clinical samples. Journal of Virological Methods, 196, 65–70. - PubMed
    1. CDC . (2019). Biosafety in Microbiological and Biomedical Laboratories (BMBL) (5th Edition). Available at: https://www.cdc.gov/labs/BMBL.html [Accessed May 21, 2020].
    1. CDC . (2020a). Considerations for optimizing the supply of Powered Air Purifying Respirators (PAPRs). Centers for Disease Control and Prevention Available at: https://www.cdc.gov/coronavirus/2019‐ncov/hcp/ppe‐strategy/powered‐air‐p... [Accessed May 30, 2020].
    1. CDC . (2020b). Information for laboratories about coronavirus (COVID‐19). Available at: https://www.cdc.gov/coronavirus/2019‐ncov/lab/lab‐biosafety‐guidelines.html [Accessed May 21, 2020].
Internet Resources
    1. https://www.osha.gov/laws‐regs/regulations/standardnumber/1910/1910.134
    1. https://www.who.int/publications‐detail/laboratory‐biosafety‐guidance‐re...
    1. https://osp.od.nih.gov/biotechnology/interim‐lab‐biosafety‐guidance‐for‐...
    1. https://www.cdc.gov/sars/guidance/f‐lab/app5.html

Publication types